This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Article
Cristina Royo-Cebrecos
Hospital Nostra Senyora Meritxell
Corresponding Author
ORCiD: https://orcid.org/0000-0003-2554-4656
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Andorra is a small country located in the Pyrenees attracting millions of visitors, mainly for ski tourism. We estimated SARS-CoV-2 seroprevalence in the entire country by universal serological testing. From 4–28 May, 2020 two cross sectional serological surveys were conducted using a rapid serological test (nCOV IgG/IgM). 72,964 inhabitants (96.1% of the population) participated. Overall seroprevalence was 11.0%. The odds of being seropositive was higher among seasonal workers (OR 1.87; 95% CI 1.57–2.23), students (OR 1.64; 95% CI 1.48–1.82) or in the population living in La Massana region (OR 2.65; 95% CI 2.43–2.89). A higher seroprevalence was observed in those familiar nuclei with greater numbers of cohabitants: 18% in families with 6 household members or more; 13% in medium size families (3/4/5 people) and 12% in small size (1 to 2 people) nuclei (p < 0.001). Seasonal workers, students and inhabitants based in ski-related areas presented a higher seroprevalence. Mass antibody screening allows to identify infection hotspots and should contribute to the design of tailored interventions to prevent SARS-CoV-2 transmission.
Keywords
SARS-CoV-2, Andorra, serological testing
Figure 1
Figure 1
Figure 2
Figure 2
There is NO Competing Interest.
This is a list of supplementary files associated with this preprint. Click to download.
- SupplementaryAppendixNatcommMassserologicalscreening.docx
Supplementary Mass serological screening SARS-CoV-2
- SupplementaryAppendixNatcommMassserologicalscreening.docx
Supplementary Mass serological screening SARS-CoV-2
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 03 Dec, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Article
Cristina Royo-Cebrecos
Hospital Nostra Senyora Meritxell
Corresponding Author
ORCiD: https://orcid.org/0000-0003-2554-4656
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 03 Dec, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Andorra is a small country located in the Pyrenees attracting millions of visitors, mainly for ski tourism. We estimated SARS-CoV-2 seroprevalence in the entire country by universal serological testing. From 4–28 May, 2020 two cross sectional serological surveys were conducted using a rapid serological test (nCOV IgG/IgM). 72,964 inhabitants (96.1% of the population) participated. Overall seroprevalence was 11.0%. The odds of being seropositive was higher among seasonal workers (OR 1.87; 95% CI 1.57–2.23), students (OR 1.64; 95% CI 1.48–1.82) or in the population living in La Massana region (OR 2.65; 95% CI 2.43–2.89). A higher seroprevalence was observed in those familiar nuclei with greater numbers of cohabitants: 18% in families with 6 household members or more; 13% in medium size families (3/4/5 people) and 12% in small size (1 to 2 people) nuclei (p < 0.001). Seasonal workers, students and inhabitants based in ski-related areas presented a higher seroprevalence. Mass antibody screening allows to identify infection hotspots and should contribute to the design of tailored interventions to prevent SARS-CoV-2 transmission.
Figure 1
Figure 1
Figure 2
Figure 2
There is NO Competing Interest.
This is a list of supplementary files associated with this preprint. Click to download.
- SupplementaryAppendixNatcommMassserologicalscreening.docx
Supplementary Mass serological screening SARS-CoV-2
- SupplementaryAppendixNatcommMassserologicalscreening.docx
Supplementary Mass serological screening SARS-CoV-2
Loading...